よむ、つかう、まなぶ。
参考資料15 COVID-19 vaccine safety update; Primary series in young children and booster doses in older children and adults, ACIP September 1, 2022 (18 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000208910_00052.html |
| 出典情報 | 第85回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、令和４年度第14回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会（合同開催）（10／7）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Summary: mRNA COVID-19 vaccine safety of primary series vaccination
in children ages 6 months–5 years
▪ Initial safety findings of both mRNA COVID-19 vaccines (Pfizer-BioNTech and
Moderna) are consistent with those observed in the clinical trials
▪ Systemic and local reactions are commonly reported adverse events
▪ Vaccination errors are also being reported to VAERS
▪ No unexpected safety findings to date
▪ No evidence of an increased risk for myocarditis following mRNA COVID-19
vaccination in children ages 6 months–5 years
18
in children ages 6 months–5 years
▪ Initial safety findings of both mRNA COVID-19 vaccines (Pfizer-BioNTech and
Moderna) are consistent with those observed in the clinical trials
▪ Systemic and local reactions are commonly reported adverse events
▪ Vaccination errors are also being reported to VAERS
▪ No unexpected safety findings to date
▪ No evidence of an increased risk for myocarditis following mRNA COVID-19
vaccination in children ages 6 months–5 years
18